ArticleMolecular medicine reports2026
Rapamycin improves endometriosis‑related infertility involving ovarian senescence via the PPARα/IGFBP2 pathway.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- p16 Beyond Senescence: Cancer Biology Lessons Applied to Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- The Impact of Oxidative Stress Imbalance on Ovarian Function and Its Mechanisms.International journal of general medicine · 2026Review
- Hydralazine Attenuates Lipopolysaccharide-Induced Murine Myocardial Dysfunction by Inhibition of Semicarbazide-Sensitive Amine Oxidase.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis‑associated infertility is considered to be linked to cellular senescence. The present study assessed whether rapamycin, a senescence inhibitor, ameliorates endometriosis‑associated infertility by upregulating peroxisome proliferator‑activated receptor α (PPARα) and insulin‑like growth factor‑binding protein 2 (IGFBP2) expression. In the present study, mice were randomized into three groups: Control (CTL), endometriosis (EM) and rapamycin‑treated endometriosis (EM‑R). The expression of senescence‑associated markers at both the tissue and cellular levels were examined as well as the potential mechanisms underlying the effects of rapamycin treatment using ELSA and quantitative PCR. Oxidative stress markers (malondialdehyde and 8‑hydroxy‑2'‑deoxyguanosine) in peritoneal fluid were significantly elevated in the EM group compared with in the EM‑R and CTL groups, whilst antioxidant levels (superoxide dismutase and glutathione peroxidase) were lowest in the EM group. Senescence markers (p16, p21 and γH2AX) and gonadotropin receptors (follicle‑stimulating hormone receptor and luteinizing hormone receptor) were highest and lowest, respectively, in the EM group. Ovarian analysis revealed a higher primordial follicle count but fewer mature follicles in the EM group compared with the EM‑R and CTL groups. Rapamycin treatment increased PPARα and IGFBP2 expression in ovarian tissues, suggesting that its therapeutic effect on endometriosis‑related infertility may involve the PPARα/IGFBP2 pathway by mitigating cellular senescence. Rapamycin may potentially ameliorate follicular development in patients with endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.